- Home
- UNM vs EXEL Comparison
UNM vs EXEL Comparison
Compare UNM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNM
- EXEL
- Stock Information
- Founded
- UNM 1848
- EXEL 1994
- Country
- UNM United States
- EXEL United States
- Employees
- UNM N/A
- EXEL N/A
- Industry
- UNM Accident &Health Insurance
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNM Finance
- EXEL Health Care
- Exchange
- UNM Nasdaq
- EXEL Nasdaq
- Market Cap
- UNM 14.4B
- EXEL 11.6B
- IPO Year
- UNM 1986
- EXEL 2000
- Fundamental
- Price
- UNM $78.17
- EXEL $41.59
- Analyst Decision
- UNM Buy
- EXEL Buy
- Analyst Count
- UNM 13
- EXEL 18
- Target Price
- UNM $86.85
- EXEL $39.59
- AVG Volume (30 Days)
- UNM 1.0M
- EXEL 2.9M
- Earning Date
- UNM 07-29-2025
- EXEL 08-05-2025
- Dividend Yield
- UNM 2.15%
- EXEL N/A
- EPS Growth
- UNM 26.80
- EXEL 237.58
- EPS
- UNM 8.54
- EXEL 2.20
- Revenue
- UNM $12,778,600,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- UNM $4.41
- EXEL $9.51
- Revenue Next Year
- UNM $3.96
- EXEL $10.91
- P/E Ratio
- UNM $9.16
- EXEL $18.87
- Revenue Growth
- UNM 1.82
- EXEL 24.49
- 52 Week Low
- UNM $48.38
- EXEL $21.36
- 52 Week High
- UNM $84.48
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- UNM 42.18
- EXEL 49.88
- Support Level
- UNM $77.32
- EXEL $41.31
- Resistance Level
- UNM $79.30
- EXEL $43.50
- Average True Range (ATR)
- UNM 1.56
- EXEL 0.95
- MACD
- UNM -0.43
- EXEL -0.37
- Stochastic Oscillator
- UNM 14.70
- EXEL 20.00
About UNM Unum Group
Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum USA, Unum International, Closed Block, Colonial Life, and Corporate. The majority of the revenue is earned from the Unum USA segment. The firm markets its products through brokers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.